Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Ligand Pharmaceuticals Incorporated focuses on developing and commercializing innovative therapeutics through its proprietary technologies and partnerships. The company leverages its extensive library of drug candidates and collaborations with major pharmaceutical firms to drive growth, particularly in the oncology and rare disease sectors.
Ligand generates revenue primarily through royalties from sales of partnered drugs, leveraging its proprietary technologies to enhance drug development. The company has significant pricing power due to its unique drug delivery platforms and strong relationships with large pharmaceutical companies, which provide a steady stream of income from milestone payments.
Approval and commercialization of partnered drugs, particularly in oncology
New licensing agreements with major pharmaceutical companies
Progress in clinical trials for proprietary drug candidates
Changes in royalty revenue from existing partnerships
Regulatory changes impacting drug approval processes
Technological disruption in drug development
Emerging biotech firms with innovative therapies
Increased competition from generic drugs
Potential liquidity risks if cash flow does not improve
Dependence on a limited number of partnerships for revenue
moderate - Ligand's revenue is somewhat linked to the overall healthcare spending, which can be influenced by economic cycles and consumer spending.
Interest rates affect Ligand's cost of capital for potential acquisitions and R&D investments. Higher rates could compress valuation multiples, impacting stock performance.
minimal - Ligand's low debt levels (Debt/Equity of 0.45) reduce its exposure to credit conditions.
growth - Investors are likely attracted to Ligand due to its rapid revenue growth and potential for high returns from successful drug developments.
high - The stock has shown significant price fluctuations, evidenced by a 164.3% return over the past year.
